As a surgical oncologist, I care for patients with benign and malignant (cancerous) diseases of the liver, bile duct, gallbladder, and pancreas. Many patients come to me with cancer that has spread, or metastasized, from the colon to the liver. I also have an interest in benign pancreatic tumors, which do not necessarily merit immediate removal but should be carefully watched for any changes that warrant surgery. The tumors that I treat are rare and many forms were once thought to be incurable. But because of innovative research, largely done at Memorial Sloan Kettering, and my close collaboration with our radiologists and medical oncologists, I can often offer patients a good chance at long-term survival and, in many cases, cure. Our team of five board-certified surgeons currently performs between 800 and 1,000 hepatopancreatobiliary operations annually.
At MSK, I am honored to hold the Enid A. Haupt Chair in Surgery. I also serve as Vice Chair of the MSK Research Council, which oversees all high-risk research protocols throughout the hospital. In addition, I am Program Director for two prestigious training fellowships, in Surgical Oncology and Hepatopancreatobiliary Surgery. Externally, I am Vice Chair of the National Comprehensive Cancer Network (NCCN) panel on Clinical Practice Guidelines in Hepatobiliary Cancers. For years I have worked closely with the NCCN to help shape and write these treatment guidelines that are today followed in the US and much of the world.